Carnegien kommentit R&D jälkeen:
BEXERA: appear to be progressing according to plan, now entering the site activation phase
BLAZE ja BEXAR: Solid tumour trials advancing…both studies could provide important proof-of-concept data for BEX in solid tumours and, if successful, add meaningful value to the programme.
Osakekohtainen yhtiön käypä arvo: Our fair value range is EUR0.8–1.2 per share
Yhteenveto: we believe Faron is making solid operational progress and see considerable potential for BEX. However, weak sentiment towards European micro-cap biotechs and the convertible debt structure continue to weigh on the stock, we believe.